source
- European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyDrug developers are racing to make gene therapies that could replace chronic GLP-1 injections and pills with a one-and-done treatment. Now, a company based just outside of Boston is poised to becom…Endpoints · 3mo ago↗ source
- CSL sinks to nine-year low on revenue warning, $5B write-downCSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by about 4% and said it would have to take a new $5 billion impairment charge. The ...Endpoints · 3mo ago↗ source
- STAT+: Five years after disaster, a rare disease community gets new chance at treatmentSome boys had astonishing recoveries. But other boys died. Now Astellas is returning to revised gene therapy for XLMTM.